|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ZAGG Inc (NASDAQ:ZAGG), a consumer durables company based in United States, saw a decent share price growth in the teens level on the NasdaqGS over the last few months. AsRead More...
On CNBC's "Mad Money Lightning Round" , Jim Cramer said it's time to buy the oil companies because crude oil is going to $80. He thinks Royal Dutch Shell plc (ADR) ADR Class A (NYSE: RDS-A ) ...
Futures Up on China-U.S. Trade Talks, China at New 52-Week Lows Washington sent an invitation to Beijing for trade talks in late August, and the Chinese have responded in kind. They plan to send their vice minister of commerce to discuss the situation, and U.S. futures are up on the news. Not so much for […] The post Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail appeared first on Market Exclusive.
The indices have bounced off the intraday lows but when a bounce doesn't occur quickly after the open the danger of a poor close is higher. This is a market that has been struggling for a while although the indices have covered it to a great extent.
On Twitter this morning Tony Dwyer commented that "According to NFIB, Small Biz Optimism Index hit 107.9 in July, which is just 0.1% from record reading in 1983. There is no way to spin this as negative since data started (1974), we found NFIB Index peak leads recession by median 41 months" In other words, business optimism is booming and when it is this positive the likelihood of a recession in the near term is very small. The stock market doesn't always correlate with the economy but it is hard to develop a 'topping' thesis when the economic trend is so solid.
It has worked so consistently for so long that it has become a bit of a joke in the trading community. Bad news such as terrorist attacks, nuclear war with Korea, Trade wars with China and even President Donald Trump himself have consistently result in automatic and energetic buying.
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.
Ziopharm (ZIOP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 12 cents per share. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss ...
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 8.51% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.67. Losses, adjusted for non-recurring costs and stock option expense, were 43 cents per share. The results exceeded ...
Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.
Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $1.58 billion.